JP2023103455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023103455A5 JP2023103455A5 JP2023083756A JP2023083756A JP2023103455A5 JP 2023103455 A5 JP2023103455 A5 JP 2023103455A5 JP 2023083756 A JP2023083756 A JP 2023083756A JP 2023083756 A JP2023083756 A JP 2023083756A JP 2023103455 A5 JP2023103455 A5 JP 2023103455A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- seq
- fgf21
- mutations
- fgf21 polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 11
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 102100020683 Beta-klotho Human genes 0.000 claims 2
- 101710104526 Beta-klotho Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102100036407 Thioredoxin Human genes 0.000 claims 1
- 229940050528 albumin Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 229940094937 thioredoxin Drugs 0.000 claims 1
- 108060008226 thioredoxin Proteins 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529215P | 2017-07-06 | 2017-07-06 | |
| US62/529,215 | 2017-07-06 | ||
| JP2019572539A JP7316946B2 (ja) | 2017-07-06 | 2018-07-05 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572539A Division JP7316946B2 (ja) | 2017-07-06 | 2018-07-05 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023103455A JP2023103455A (ja) | 2023-07-26 |
| JP2023103455A5 true JP2023103455A5 (enExample) | 2024-04-12 |
Family
ID=64950347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572539A Active JP7316946B2 (ja) | 2017-07-06 | 2018-07-05 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
| JP2023083756A Pending JP2023103455A (ja) | 2017-07-06 | 2023-05-22 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572539A Active JP7316946B2 (ja) | 2017-07-06 | 2018-07-05 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11365228B2 (enExample) |
| EP (1) | EP3649157A4 (enExample) |
| JP (2) | JP7316946B2 (enExample) |
| CN (1) | CN110997726B (enExample) |
| AU (1) | AU2018297285A1 (enExample) |
| CA (1) | CA3069143A1 (enExample) |
| WO (1) | WO2019010314A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2726511B1 (en) | 2011-07-01 | 2019-08-07 | NGM Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| EP2925775B1 (en) | 2012-11-28 | 2020-09-16 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| KR102724421B1 (ko) | 2012-12-27 | 2024-10-30 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법 |
| CA2951153A1 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN111420030B (zh) * | 2020-05-12 | 2021-01-29 | 江南大学 | Fgf21在制备用于治疗结直肠癌药物中的应用 |
| CN113735959B (zh) | 2021-03-12 | 2023-07-04 | 江南大学 | 一种治疗nash的fgf类似物 |
| CN113105561B (zh) * | 2021-04-30 | 2021-12-03 | 江南大学 | 一种双靶点融合蛋白的制备方法和应用 |
| WO2025059130A1 (en) * | 2023-09-11 | 2025-03-20 | Yale University | Constructs for modulating fgf21/fgfr/beta-klotho signaling pathway and treating diseases and disorders, and methods thereof |
| CN118852466B (zh) * | 2024-08-08 | 2025-03-28 | 郑州大学第三附属医院(河南省妇幼保健院) | Klotho修饰的CAR-T结构及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| AU2008275559B2 (en) | 2007-04-02 | 2014-04-10 | Genentech, Inc. | Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| EP2558497A2 (en) * | 2010-04-15 | 2013-02-20 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
| CA2835101A1 (en) | 2011-05-10 | 2012-11-15 | Amgen Inc. | Method of identifying compounds that specifically modulate the interaction of fgfr1 and .beta.-klotho |
| EP2726511B1 (en) | 2011-07-01 | 2019-08-07 | NGM Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| WO2013027191A1 (en) | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
| US9475856B2 (en) | 2012-03-02 | 2016-10-25 | New York University | Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
| US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
| US9400677B2 (en) | 2013-01-02 | 2016-07-26 | Apple Inc. | Adaptive handling of priority inversions using transactions |
| US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| EA201791238A1 (ru) | 2014-12-04 | 2018-02-28 | Новартис Аг | Способы и композиции, в которых используются варианты полипептидов klotho |
| US10456442B2 (en) | 2015-06-18 | 2019-10-29 | Albert Einstein College Of Medicine | FGF receptor ligands for treating diabetes and obesity |
| CN108602884B (zh) * | 2015-11-08 | 2024-06-25 | 豪夫迈·罗氏有限公司 | 筛选多特异性抗体的方法 |
| WO2017180988A2 (en) * | 2016-04-15 | 2017-10-19 | Indiana University Research And Technology Corporation | Fgf21 c-terminal peptide optimization |
| US11318186B2 (en) | 2016-05-25 | 2022-05-03 | Board Of Regents, The University Of Texas System | Use of FGF21 in methods of increasing exocrine pancreatic secretion |
| WO2018026899A1 (en) | 2016-08-03 | 2018-02-08 | Joslin Diabetes Center, Inc. | Methods and compositions for treating hypoglycemia |
-
2018
- 2018-07-05 CA CA3069143A patent/CA3069143A1/en active Pending
- 2018-07-05 EP EP18827563.0A patent/EP3649157A4/en active Pending
- 2018-07-05 WO PCT/US2018/040932 patent/WO2019010314A1/en not_active Ceased
- 2018-07-05 US US16/624,895 patent/US11365228B2/en active Active
- 2018-07-05 AU AU2018297285A patent/AU2018297285A1/en not_active Abandoned
- 2018-07-05 JP JP2019572539A patent/JP7316946B2/ja active Active
- 2018-07-05 CN CN201880054775.3A patent/CN110997726B/zh active Active
-
2023
- 2023-02-28 US US18/176,172 patent/US20240083961A1/en active Pending
- 2023-05-22 JP JP2023083756A patent/JP2023103455A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023103455A5 (enExample) | ||
| JP6634402B2 (ja) | 代謝障害及び疾患の治療のための組成物、使用及び方法 | |
| RU2729161C2 (ru) | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения | |
| JP7761557B2 (ja) | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 | |
| JP2020526503A5 (enExample) | ||
| US10130688B2 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| US20090048148A1 (en) | Compositions and methods for therapeutic use | |
| JP6680758B2 (ja) | 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 | |
| US10617741B2 (en) | Compositions and methods for oral delivery of therapeutic cargo | |
| KR20070004078A (ko) | 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도 | |
| JP2005507637A5 (enExample) | ||
| WO2010105573A1 (zh) | 抗血管新生融合蛋白 | |
| CN105189542A (zh) | 用于治疗庞贝氏症的方法和组合物 | |
| JPWO2019157224A5 (enExample) | ||
| JP7479539B2 (ja) | インターロイキン－２２の治療用誘導体 | |
| KR20090039787A (ko) | 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도 | |
| KR20090092336A (ko) | 인슐린 감수성 및 지질 프로필을 개선하기 위한 장기 작용 ｇｌｐ-1 수용체 작용제의 용도 | |
| JP2023546090A (ja) | Ｇｌｐ－１／ｇｉｐ二重作用剤、その持続型結合体、及びそれを含む薬学的組成物 | |
| JP2019527053A (ja) | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 | |
| JP2009510999A (ja) | キメラ治療剤 | |
| JP2024517329A (ja) | インターロイキン－２２の治療的誘導体 | |
| CN117616035A (zh) | 白介素-22的治疗性衍生物 | |
| JP2009517009A5 (enExample) | ||
| WO2008003748A2 (en) | Cd300lg polypeptides and their use in treating autoimmune diseases | |
| KR20220010462A (ko) | 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도 |